CD47 and acute myeloid leukemia: Preclinical evidence is strongest for the combination of azacitidine and anti-CD-47 antibodies, with the combination leading to higher phagocytosis of AML cells in vitro, induction of proposed pro-phagocytic signals including increased calreticulin, long-term remission in AML xenograft mice models [111].